and the regulatory risk that comes with it. The stock's 34.47% one-week surge reflects how much of that overhang had been priced in. BofA's new $23 target sits close to current trading levels, while Deutsche Bank's $28 target implies more room to run if the Novo relationship matures.For Teladoc, Deutsche Bank's $11 Buy target against a $5.30 current price represents substantial implied upside and reflects the firm's view that the market is underpricing the value of the Integrated Care segment and a potentia ...